Evelyn Despierre1, Betül T Yesilyurt, Sandrina Lambrechts, Nick Johnson, René Verheijen, Maria van der Burg, Antonio Casado, Gordon Rustin, Els Berns, Karin Leunen, Frédéric Amant, Philippe Moerman, Diether Lambrechts, Ignace Vergote. 1. *Gynecologic Oncology and Leuven Cancer Institute, University Hospitals Leuven; and †Laboratory for Translational Genetics, Department of Oncology, Katholieke Universiteit Leuven; and ‡Vesalius Research Center, VIB, Leuven, Belgium; §Royal United Hospital NHS Trust, Gynaecological Oncology, Bath, United Kingdom; ∥Division of Women and Baby, Department of Gynaecological Oncology, University Medical Centre Utrecht; and ¶Department of Medical Oncology, Erasmus University Medical Center-Cancer Institute, Rotterdam, the Netherlands; #Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain; **Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, United Kingdom; and ††Department of Pathology, University Hospitals Leuven, Belgium.
Abstract
OBJECTIVE: Epithelial ovarian cancers (EOCs) are, although still treated as a single disease entity, often classified into type I tumors (low-grade serous, mucinous, endometrioid, clear cell) and type II tumors (high-grade serous, undifferentiated cancers, carcinosarcomas). The aim of our study was to determine the incidence, clinical relevance, and prognostic and predictive impact of somatic mutations in both types I and II EOCs. METHODS: Two hundred sixty-two evaluable, primary, high-risk stage I (grade 3, or aneuploid grade 1 or 2, or clear cell) and stage II-IV EOCs, collected at the University Hospitals Leuven and within the European Organisation for Research and Treatment of Cancer 55971 trial, were genotyped for hotspot mutations in KRAS (COSMIC [Catalogue of Somatic Mutations in Cancer] coverage >97%), BRAF (>94%), NRAS (>97%), PIK3CA (>79%), PTEN, FBXW7 (>57%), AKT2, AKT3, and FOXL2, using Sequenom MassARRAY. RESULTS: Of the 13% histopathologically classified type I tumors, 49% were KRAS or PIK3CA mutant versus only 2.9% in the type II tumors (87%). Mucinous subtypes harbored significantly more KRAS mutations than all nonmucinous tumors (50% vs 4%, P < 0.001). PIK3CA mutations were predominantly found in clear cell carcinomas (46.2%) and endometrioid carcinoma (20%) and were frequently associated with endometriosis. Moreover, low-grade serous tumors were more frequently KRAS or BRAF mutated (44%) than high-grade serous tumors (0.6%). KRAS or PIK3CA mutation did not correlate with progression-free survival or overall survival. Mutations in NRAS, PTEN, FBXW7, AKT2, AKT3, and FOXL2 were rare (<1%). CONCLUSIONS: Somatic mutations are rare in type II EOCs, whereas type I EOCs contain distinct diseases with different driver mutations. In general, these tumors respond worse to standard paclitaxel carboplatin therapy. Clinical trials with molecular targeted therapy in the different subtypes of type I tumors are urgently needed using this theragnostic information.
OBJECTIVE:Epithelial ovarian cancers (EOCs) are, although still treated as a single disease entity, often classified into type I tumors (low-grade serous, mucinous, endometrioid, clear cell) and type II tumors (high-grade serous, undifferentiated cancers, carcinosarcomas). The aim of our study was to determine the incidence, clinical relevance, and prognostic and predictive impact of somatic mutations in both types I and II EOCs. METHODS: Two hundred sixty-two evaluable, primary, high-risk stage I (grade 3, or aneuploid grade 1 or 2, or clear cell) and stage II-IV EOCs, collected at the University Hospitals Leuven and within the European Organisation for Research and Treatment of Cancer 55971 trial, were genotyped for hotspot mutations in KRAS (COSMIC [Catalogue of Somatic Mutations in Cancer] coverage >97%), BRAF (>94%), NRAS (>97%), PIK3CA (>79%), PTEN, FBXW7 (>57%), AKT2, AKT3, and FOXL2, using Sequenom MassARRAY. RESULTS: Of the 13% histopathologically classified type I tumors, 49% were KRAS or PIK3CA mutant versus only 2.9% in the type II tumors (87%). Mucinous subtypes harbored significantly more KRAS mutations than all nonmucinous tumors (50% vs 4%, P < 0.001). PIK3CA mutations were predominantly found in clear cell carcinomas (46.2%) and endometrioid carcinoma (20%) and were frequently associated with endometriosis. Moreover, low-grade serous tumors were more frequently KRAS or BRAF mutated (44%) than high-grade serous tumors (0.6%). KRAS or PIK3CA mutation did not correlate with progression-free survival or overall survival. Mutations in NRAS, PTEN, FBXW7, AKT2, AKT3, and FOXL2 were rare (<1%). CONCLUSIONS: Somatic mutations are rare in type II EOCs, whereas type I EOCs contain distinct diseases with different driver mutations. In general, these tumors respond worse to standard paclitaxelcarboplatin therapy. Clinical trials with molecular targeted therapy in the different subtypes of type I tumors are urgently needed using this theragnostic information.
Authors: Blanca L Valle; Sebastian Rodriguez-Torres; Elisabetta Kuhn; Teresa Díaz-Montes; Edgardo Parrilla-Castellar; Fahcina P Lawson; Oluwasina Folawiyo; Carmen Ili-Gangas; Priscilla Brebi-Mieville; James R Eshleman; James Herman; Ie-Ming Shih; David Sidransky; Rafael Guerrero-Preston Journal: Cancer Prev Res (Phila) Date: 2020-06-24
Authors: A Talhouk; M K McConechy; S Leung; H H Li-Chang; J S Kwon; N Melnyk; W Yang; J Senz; N Boyd; A N Karnezis; D G Huntsman; C B Gilks; J N McAlpine Journal: Br J Cancer Date: 2015-06-30 Impact factor: 7.640
Authors: Martin Gore; Allan Hackshaw; William E Brady; Richard T Penson; Richard Zaino; W Glenn McCluggage; Raji Ganesan; Nafisa Wilkinson; Timothy Perren; Ana Montes; Jeffrey Summers; Rosemary Lord; Graham Dark; Gordon Rustin; Melanie Mackean; Nicholas Reed; Sean Kehoe; Michael Frumovitz; Helen Christensen; Amanda Feeney; Jonathan Ledermann; David M Gershenson Journal: Gynecol Oncol Date: 2019-04-18 Impact factor: 5.482
Authors: Racheal Louise Johnson; Alexandros Laios; David Jackson; David Nugent; Nicolas Michel Orsi; Georgios Theophilou; Amudha Thangavelu; Diederick de Jong Journal: J Clin Med Date: 2021-12-17 Impact factor: 4.241